EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

CDK4/6 inhibitors as adjuvant therapy in early breast cancer? Uncertain benefits, guaranteed harms

Alyson Haslam, Sruthi Ranganathan, Vinay Prasad, Timothée Olivier

European Journal of Cancer · 2024

DOI: 10.1016/j.ejca.2024.114192 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Cancer, 2024. Verfasst von Alyson Haslam und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Epidemiology and Biostatistics, University of California San Francisco, 550 16th St, 2nd Fl, San Francisco, CA 94158, USA. Hauptthemen laut MEDLINE: Breast Neoplasms, Cyclin-Dependent Kinase 4, Cyclin-Dependent Kinase 6, Protein Kinase Inhibitors. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Arnold Ventures LLC.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

CDK4/6 inhibitors are oral agents inhibiting key molecules of the cell cycle regulation. In patients with endocrine receptor positive (ER+), human epidermal growth factor receptor 2 negative (HER2-) breast cancer, the combination of CDK4/6 inhibitors with endocrine therapy is an effective treatment in the metastatic setting. Now, two studies in the adjuvant setting - MonarchE (2 years of abemaciclib) and NATALEE (3 years of ribociclib) - report positive invasive disease-free survival. Here, we re-evaluate these seminal trials. First, an excess drop-out or loss-to-follow up occurred early in the control arms of both studies. Since both trials are open-label, there is concern that the patients who drop-out do not do so at random but based on socioeconomic factors and alternative options. Is it possible that the results merely appear favorable due to loss to follow up? Based on re-constructed Kaplan-Meier curves, we concluded the results of these studies remain fragile, being prone to informative censoring. Secondly, adverse events were notably higher in both trials, and some of them, like COVID-19 related deaths in NATALEE, raise serious concerns. Third, the potential costs associated with CDK4/6 inhibition given as adjuvant therapy are unprecedented. The NATALEE strategy, in particular, could affect up to 35 % of patients with newly diagnosed breast cancer, which is the cancer with the highest incidence worldwide. Without confirmatory data based on a placebo-controlled trial, or better identification of patients that would benefit from the addition of CDK4/6 inhibitors in the adjuvant setting, we argue against their routine use as adjuvant therapy in ER+ /HER2- early breast cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsCyclin-Dependent Kinase 4Cyclin-Dependent Kinase 6Protein Kinase InhibitorsFemaleHumansAminopyridinesAntineoplastic Combined Chemotherapy ProtocolsBenzimidazolesChemotherapy, AdjuvantPurinesRandomized Controlled Trials as Topic

Stichwörter der Autor:innen

AbemaciclibAdjuvantBreast cancerCDK4/6 inhibitorsInformative censoringRibociclib

Substanzen

abemaciclibAminopyridinesBenzimidazolesCDK4 protein, humanCDK6 protein, humanCyclin-Dependent Kinase 4Cyclin-Dependent Kinase 6Protein Kinase InhibitorsPurinesribociclib

Autor:innen und Institutionen

  • Department of Epidemiology and Biostatistics, University of California San Francisco, 550 16th St, 2nd Fl, San Francisco, CA 94158, USA.
  • Department of Medicine, University of Cambridge, Cambridge, United Kingdom.
  • Department of Oncology, Geneva University Hospital, 4 Gabrielle-Perret-Gentil Street, 1205 Geneva, Switzerland. Electronic address: timothee.olivier@hug.ch.

Förderung

  • Arnold Ventures LLC

Zitieren

APA

Haslam, A., Ranganathan, S., Prasad, V., & Olivier, T. (2024). CDK4/6 inhibitors as adjuvant therapy in early breast cancer? Uncertain benefits, guaranteed harms. European Journal of Cancer. https://doi.org/10.1016/j.ejca.2024.114192

Vancouver

Haslam A, Ranganathan S, Prasad V, Olivier T. CDK4/6 inhibitors as adjuvant therapy in early breast cancer? Uncertain benefits, guaranteed harms. European Journal of Cancer. 2024. doi:10.1016/j.ejca.2024.114192

BibTeX
@article{Haslam2024,
  author = {Haslam, Alyson and Ranganathan, Sruthi and Prasad, Vinay and Olivier, Timothée},
  title = {CDK4/6 inhibitors as adjuvant therapy in early breast cancer? Uncertain benefits, guaranteed harms},
  journal = {European Journal of Cancer},
  year = {2024},
  doi = {10.1016/j.ejca.2024.114192}
}
Kostenlos starten →